Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya by Patel, Anik R. et al.
Economic Evaluation Study Medicine®
OPENEconomic evaluation of mobile phone text
message interventions to improve
adherence to HIV therapy in Kenya
Anik R. Patel, RPh, MHAa,b,
∗
, Jason Kessler, MD, MPHb, R. Scott Braithwaite, MD, MScb,
Kimberly A. Nucifora, MSb, Harsha Thirumurthy, PhDc, Qinlian Zhou, PhDb,
Richard T. Lester, MDa, Carlo A. Marra, PharmD, PhDd
Abstract
Background: A surge in mobile phone availability has fueled low cost short messaging service (SMS) adherence interventions.
Multiple systematic reviews have concluded that some SMS-based interventions are effective at improving antiretroviral therapy
(ART) adherence, and they are hypothesized to improve retention in care. The objective of this study was to evaluate the cost-
effectiveness of SMS-based adherence interventions and explore the added value of retention benefits.
Methods:We evaluated the cost-effectiveness of weekly SMS interventions compared to standard care among HIV+ individuals
initiating ART for the first time in Kenya. We used an individual level micro-simulation model populated with data from two SMS-
intervention trials, an East-African HIV+ cohort and published literature. We estimated average quality adjusted life years (QALY) and
lifetime HIV-related costs from a healthcare perspective. We explored a wide range of scenarios and assumptions in one-way and
multivariate sensitivity analyses.
Results:We found that SMS-based adherence interventions were cost-effective by WHO standards, with an incremental cost-
effectiveness ratio (ICER) of $1,037/QALY. In the secondary analysis, potential retention benefits improved the cost-effectiveness
of SMS intervention (ICER=$864/QALY). In multivariate sensitivity analyses, the interventions remained cost-effective in most
analyses, but the ICER was highly sensitive to intervention costs, effectiveness and average cohort CD4 count at ART initiation.
SMS interventions remained cost-effective in a test and treat scenario where individuals were assumed to initiate ART upon HIV
detection.
Conclusions: Effective SMS interventions would likely increase the efficiency of ART programs by improving HIV treatment
outcomes at relatively low costs, and they could facilitate achievement of the UNAIDS goal of 90% viral suppression among those on
ART by 2020.
Abbreviations: AIDS = acquired immune deficiency syndrome, ART = antiretroviral therapy, ASC = adherence under standard
care, HIV = human immunodeficiency virus, HSUV = health state utility value, RCT = randomized controlled trial, SMS = short
messaging service, WHO = World Health Organization.
Keywords: cost-effectiveness, drug adherence, HIV, implementation science, mHealth, mobile phone, SMS1. Introduction
Mobile phones are a viable technology to support healthcare
delivery because of their widespread global availability.[1] The
global technology boom has fueled an emergence of mobile health
applications delivered through text-messages, also known as short
messaging service (SMS), which are now the most widely usedEditor: Dimitrios Paraskevis.
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people in Kenya.[3] Life-saving antiretroviral therapy (ART)
has become increasingly available and has improved HIV
outcomes.
The World Health Organization (WHO) has recently an-
nounced that 17 million people world-wide were on ART at the
end of 2015, and they are advocating for expanded testing and
treatment strategieswhereby everyonewho tests positive forHIV is
immediately eligible for treatment.[4] Additionally, the UNAIDS
90-90-90 goals aim to have 90% of global HIV cases virally
suppressed by 2020.[5] Adherence above 90% to 95% is needed to
achieve viral suppression for older regimens of ART that are used
inmany parts of theworld; however, adherence has been shown to
be lower in several populations.[6,7] Retention rates are also poor,
as many individuals prematurely drop out of care. In African ART
programs, average patient retention 3 years after ART initiation is
estimated to be 65%.[7] The major consequence of both
nonadherence and dropout from care is reduced viral suppression,
which can accelerate progression to acquired immune deficiency
syndrome (AIDS) as well as increase HIV transmission.
Systematic reviews of all interventions that target ART
nonadherence suggested that SMS interventions have one of
the strongest levels of supportive evidence.[6,8] Independently
conducted systematic reviews of RCTs on SMS-based adherence
interventions concluded that weekly delivered reminders and
SMS-based interactive patient engagement improved adherence
to ART (RR 1.28).[8–10] Further, 2-way SMS interventions are
hypothesized to improve 1 year retention in care and showed a
statistically nonsignificant increase in 1 trial (RR 1.69, P=
0.094).[11] The combined evidence supporting the use of SMS
interventions led to the World Health Organization (WHO)
recommending SMS to promote adherence in their consolidated
guidelines on the use of ART.[12]
Despite the compelling evidence, effective SMS adherence
interventions have not been implemented to sufficient scale to
assist in reaching global HIV control targets. Previous studies
have used computer simulation models to determine the cost-
effectiveness of ART expansion.[3,13,14] However, there have
been no cost-effectiveness evaluations describing the incremental
value of SMS-based adherence interventions, so it is unclear how
investment in them would compare to expansion of ART or to
other interventions.[6,15] Thus, the objective of this study was to
examine the cost-effectiveness of a weekly SMS-based adherence
intervention compared to usual care in people living with HIV/
AIDS initiating ART in Kenya.2. Methods
2.1. Definitions
We define adherence as the extent to which individuals’ take daily
doses of ART as prescribed and use a threshold of 90% to
differentiate “highly adherent” from “sub-optimally adherent”
individuals. We define adherence under standard care (ASC) as
the proportion of individuals who are highly adherent under the
standard of care in Kenya, which includes 1 or 2 adherence
counseling sessions at ART initiation.[11] Also under standard
care, peer-support, and participation in support groups were
suggested, but not mandated.[11] We define retention-in-care as
consistent prescription pick-up of ART, reporting for regular care
as prescribed and regular CD4 testing. Dropout refers to an
individual who has disengaged from care and no longer receiving
regular care or medication refills.22.2. Model structure
The target population of this analysis was Kenyan people living
with HIV/AIDS initiating ARTwho own or have access to mobile
phones. We revised a previously developed simulation model of
HIV progression to estimate the long-term health and economic
impacts of weekly short message service (SMS) adherence
interventions compared to standard care (Fig. 1).[16,17] Ethics
approval was not required for this simulation-based study. The
simulation modeled relationships between multiple inputs
including CD4 count, viral load, and adherence to ART and
used a daily time cycle. The simulation tracked daily events
including adherence to 1st or 2nd line regimens of ART, CD4
testing, and symptomatic-AIDS events (eg, hospitalization). Daily
adherence was based on an individuals’ propensity to adhere, and
their adherence affected their rate of drug resistance development
and rate of viral suppression or rebound. The simulation reflected
progression and remission of HIV through severity states based
on patient-level characteristics (eg, CD4 count), which were used
to calculate cost and quality-adjusted life years (QALYs) as a
function of time spent in these states. A simulated individual’s
viral load and CD4 count were modeled as continuous variables
that varied over time as a function of active ART use and daily
ART adherence. The relationship between adherence and viral
load suppression is described in greater detail in the technical
appendix, http://links.lww.com/MD/B571.
Disengagement from care assumed individuals were off drug
therapy and did not attend regular appointments. Once
disengaged, CD4 declined based on individual characteristics
and on the natural history of disease.[18] The CD4 count
continued to decline until a simulated individual either returned
to care or died. The probability of returning to care or death was
a function of an individual’s CD4 count, and the probabilities
increased as CD4 count declined. Individuals were at risk of
dropout and return to care based on rates observed in a large East
Africa cohort.[19] The potential for SMS intervention to reduce
dropout was explored in secondary analysis by reducing the rate
of dropout.2.3. SMS interventions effectiveness
We conducted a literature review of SMS interventions and found
multiple systematic reviews that summarized the adherence
effects of weekly SMS (Table 1).[8–10] The review by Hovarth
et al[9] incidentally only included RCTs from Kenya and
presented the most conservative SMS intervention effect size.
We chose to use the conservative effect size in our base case
analysis to present a conservative estimate of cost-effectiveness.
The published pooled effect size was used in this analysis (RR=
1.28), and the effectiveness input was varied over the bounds of
the published 95% confidence interval (RR=1.04–1.59). In
Hovarth et al., 2 SMS RCTs were included in their weekly
intervention analysis: one studied 1-way supportive SMS
reminders, while the other studied 2-way SMS-based individual
engagement. The interventions and intervention trials are
described in greater detail in the technical appendix, http://
links.lww.com/MD/B571.2.4. Simulating SMS interventions
The intervention costs consisted of initial staff training, SMS
airtime, overhead and technology maintenance, and in the case of
2-way SMS-based patient engagement, labor to respond to
Figure 1. An influence diagram of the individual microsimulation model structure. (A) Adherence directly impacted the rate of viral suppression and HIV disease
progression, which determined the prognosis for modeled individuals. SMS interventions improve individual adherence and thus impact health outcomes. (B)
Individuals could disengage from care during the simulation with probabilities matching East African data. Once disengaged, simulated individuals could reengage
with a health system or die out of care. SMS interventions were simulated to reduce the probability of disengagement. HIV=human immunodeficiency virus, SMS=
short messaging service.
Patel et al. Medicine (2017) 96:7 www.md-journal.comindividuals experiencing problems. Although trial data suggest
the current average cost of the SMS interventions to be lower, we
assumed a $15 annual cost per individual in our base case, to
provide a conservative estimate of cost-effectiveness (Table 1).
We conducted multivariate sensitivity analyses to show theTable 1
Simulation input parameters.
Model parameter in simulation Ba
Population characteristics
Age (mean)
Average baseline CD4 count, cells/mm3
Viral load (Log 10 units)
% Male
Costs (2016 USD)
Initial ART regimen
Second ART regimen
Average cost of inpatient care per episode
Annual outpatient care cost excl. ART
Cost of viral load test
Cost of CD4 test
Health state utility values
Decrease in utility with ART
Utility with CD4<100cells/mm3
Utility with CD4 100 to 200cells/mm3
Utility with CD4>200 cells/mm3
Drug efficacy and retention parameters
Viral load decrement with ART of 2 NRTI+efavirenz at 100% adherence
Viral load decrement with ART consisting of boosted PI 100% adherence
Proportion highly adherent with standard care
Probability of disengagement from clinic, per month 0
Relative risk of treatment failure when disengaged
Intervention costs and effects
Relative risk of adherence to ART
Relative risk reduction of dropout from care
Annual cost of intervention per patient†
AMPATH=Academic Model for the Prevention and Treatment of HIV, ART= antiretroviral therapy, N/A=
∗
Nagide PI, personal communication, July 2016.
† Hwang B, personal communication, July 2016; detailed breakdown of costs are in the technical appe
3relationship between intervention costs and other key model
inputs. We applied a lifetime annual cost in most of our analyses,
but tested a 1-time cost in the 1st year in sensitivity analysis.
Additional details of the SMS intervention costs are discussed in
the technical appendix, http://links.lww.com/MD/B571.se case Plausible range Source
39 N/A AMPATH
126 250, 300, and 500 AMPATH
4.5 N/A AMPATH
38% N/A AMPATH
$131 Varied from 0.5 to 1.5 Personal communication∗
$286 Varied from 0.5 to 1.5 Personal communication∗
$429 Varied from 0.5 to 1.5 AMPATH
$319 Varied from 0.5 to 1.5 AMPATH
$25 Varied from 0.5 to 1.5 Personal communication∗
$5.5 Varied from 0.5 to 1.5 Personal communication∗
0.053 Not varied [20]
0.81 0.65 and 1 [11,21]
0.87 0.71 and 1 [21]
0.94 0.73 and 1 [21]
3.09 Not varied [22]
2.68 Not varied [22]
50% 30% to 90% [11,23]
.4–2.4% Not varied [24]
3.32 Not varied [24]
1.28 1.04 to 1.59 [9]
1.69 1 to 3.23 [11]
$15 $5 to $50 Personal communication†
not available, NRTI=nucleoside analog reverse-transcriptase inhibitors, PI=protease inhibitor.
ndix, http://links.lww.com/MD/B571.
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suboptimally adherent individuals (adherence<90%) and in-
creased the proportion of highly adherent individuals (adherence
between 90% and 100%). We modeled population adherence
proportions observed in the both SMS intervention RCTs.[11,23]
A key difference between the trials was the endpoint proportion
of highly adherent individuals in the control group (Fig. S2, http://
links.lww.com/MD/B570). The endpoint control group adher-
ence was used as a proxy for ASC. The Lester et al trial found
50% were highly adherent and the Pop-Eleches et al trial found
that 40% of individuals were highly adherent in the control
group, suggesting differences in ASC across Kenyan settings. The
relationship between level of adherence and HIV progression is
described in greater detail in the technical appendix, http://links.
lww.com/MD/B571.2.5. Additional simulation settings
The remaining parameters came from literature reviews and an
EastAfricanHIV cohort data (Table 1). Some characteristics of the
simulated cohort, including rate of disengagement, came from the
Academic Model for the Prevention and Treatment of HIV
(AMPATH) cohort, a multiyear cohort in East Africa.[24,25] Costs
were evaluated from a health system perspective. Drug costs for
each regimen of ART were provided through personal communi-
cation with research staff in a Nairobi-based ART clinic (Nagide
PI, personal communication, July 2016). ART regimens used by
simulated individuals reflected current Kenyan treatment guide-
lines, which are based on WHO treatment guidelines.[12]
Treatment costs, including hospitalization and outpatient HIV
care costs, were derived from AMPATH databases. Health state
utility values (HSUVs) were based on CD4 count categories of
<100cells/mm3, 101 to 200cells/mm3, and >200cells/mm3 and
were derived from published literature.[21,26] Base case HSUV
came from a US study, but HSUV measured as part of the Lester
et al trial were included in a sensitivity analysis. We assumed a
lifetime adherence benefit of the SMS interventions and applied
lifetime annual costs of the intervention. We discounted cost and
QALY outcomes at 3%based onWHOguidelines, andwe used a
lifetime horizon. TheWHO suggests that an intervention in select
African countries, including Kenya, is cost-effective at less than
$US 6461/QALY and very cost-effective at less than $US 2154/
QALY.[27] We used these thresholds to interpret the final results.
The model outputs include individual level outcomes, but not
secondary transmission. The model has been validated through
its ability to predict clinical outcomes matching North American
and East African cohort data.[13,16] We recalibrated the model to
east-African data after making revisions (technical appendix: Fig.
S1A to S1D, http://links.lww.com/MD/B571). Average outcomes
of a simulated cohort of 1 million individuals were reported and
used to calculate incremental cost-effectiveness ratios (ICERs).
Additional technical detail about the model and calibration can
be found in the technical appendix, http://links.lww.com/MD/
B571, and previous publications.[13,16,17]3. Analyses
3.1. Base case analyses
We compared SMS-based adherence interventions to standard-
care and summarized results using incremental cost-effectiveness
ratios (ICER). Our base case analysis focused on adherence
improvements, excluding retention benefits. For the base case4analysis, we conservatively chose the Lester et al control group to
reflect ASC (Fig. S2, http://links.lww.com/MD/B570), but report
the results using the ASC from both trials separately. At the time
of analysis, guidelines suggest initiating ART at a CD4 count of
500cells/mm3; however, a shift is occurring in many parts of
Kenya and elsewhere toward immediate ART initiation upon
detection.We assumed an initiation threshold of 500cells/mm3 in
the base case, but explored no threshold in sensitivity analyses.3.2. Secondary analyses
Retention in care may have independent benefits from adherence
on HIV treatment outcomes. Based on trends in observed
retention in care benefits that fell below usual statistical
significance thresholds in the Lester et al trial, a secondary
analysis included both adherence and retention outcomes. We
varied the effectiveness input values for both adherence and
retention effects to examine the change in ICER in a multivariate
analysis. We repeated these analyses across a wide range of ASC
assumptions (30%–90%).
3.3. Sensitivity analyses
We performed a series of multivariate and univariate sensitivity
analyses show the impact of important simulation inputs and
assumptions on the estimated ICER. In the 1st multivariate
sensitivity analysis, we varied the ASC (40%–60%), average
baseline CD4 count (126, 250, and 500), intervention costs
($5–$50), and intervention adherence effectiveness (RR=
1.04–1.59). In the 2nd multivariate sensitivity analysis, we
varied the intervention costs ($5–$50), intervention adherence
effectiveness (RR 1.04–1.59), costs of ART (1, 1.5, and 2),
and costs of HIV care (1, 1.5, and 2). In the final
multivariate sensitivity analysis, we varied the adherence
effectiveness across the range of published effect size (RR=
1.04–1.59), the retention effectiveness (RR=1–3.23), and ASC
(30%–90%). In the remaining 2 sensitivity analyses, we explored
a shorter durability of SMS intervention effects and tested
alternative HSUVs for HIV health states. Details of the final 2
sensitivity analyses are in the technical appendix, http://links.
lww.com/MD/B571.3.4. Test and treat scenario analysis
This scenario considers the value of SMS interventions under the
updated WHO test and treat guidelines, which assumes immediate
ART initiation uponHIV detection. Current average CD4 counts at
ART initiation remain low,[28] but in time, enhanced testing and
identification of HIV cases might lead to a higher average baseline
CD4 count at ART initiation. We assumed that the test and treat
scenariowould be associatedwith an increase in averageCD4 count
at ART initiation (from the base case of 126 to 500cells/mm3). We
tested 3 values of ASC (40%–60%) in this multivariate evaluation
and varied the intervention effectiveness over the uncertainty range
(RR 1.04–1.59).4. Results
4.1. Base case analyses
Based on the conservative ASC observed in the Lester et al trial
(50%), discounted QALYs rose from 12.73 QALYs to 12.94
QALYs. Using discounted costs and QALYs, the ICER was
$1037/QALY, which was below the very cost-effective threshold
Table 2
Incremental cost-effectiveness of SMS intervention: base case with adherence effects.
Simulation description
∗
Discounted costs
(2016 USD)
Discounted
QALY
ICER
(USD/QALY)
Undiscounted mean
survival time, years
Population adherence under standard care of 40%
Standard care $7049 12.52 Reference 22.11
SMS mean effect $7292 12.79 $920 22.64
Range† ($7186 to $7379) (12.57 to 12.96) ($746 to $2866) (22.21 to 22.99)
Population adherence under standard care of 50%
Standard care $7147 12.73 Reference 22.53
SMS mean effect $7368 12.94 $1037 22.95
Range† ($7281 to $7443) (12.76 to 13.10) ($807 to $3712) (22.60 to 23.26)
ICER= incremental cost-effectiveness ratio, QALY=quality-adjusted life year, SMS= short messaging service.
∗
Intervention cost=$15USD per patient per year.
† Range is based on variation of the SMS intervention effectiveness alone.
Patel et al. Medicine (2017) 96:7 www.md-journal.comby WHO standards. Lifetime outcomes based on adherence
benefits are presented in Table 2. Based on the ASC observed in
the Pop-Eleches et al trial (40%), average survival of the cohort
declined, but the difference attributable to SMS interventions
increased. Discounted QALYs rose from 12.52 to 12.79 QALY.
Using discounted costs and QALYs, the ICER was $920/QALY,
suggesting the SMS interventions are more efficient in popula-
tions of lower average ASC.
4.2. Secondary analyses
When SMS intervention retention effects were added to
adherence effects, average discounted QALY of the simulated
cohort improved beyond the base case analysis (13.29 vs 12.94
QALY). The ICER decreased relative to the base case analysis
($864 vs $1037/QALY), suggesting SMS interventions become
more efficient if retention is also improved. Lifetime outcomes
based on SMS-based adherence intervention with retention
benefits are presented in Table 3.
4.3. Sensitivity analyses
We tested the robustness of our results by simultaneously varying
key model inputs (Fig. 2, Fig. S4 and Appendix A, http://links.
lww.com/MD/B570). In Fig. 2, threshold values are suggested for
the SMS intervention costs at different levels of the other 3
variables. Under an assumption of strong intervention effective-
ness within the range, the SMS interventions could cost up to $50
per patient per year and remain cost-effective in all scenarios.
Conversely, at the lower end of the intervention effectiveness
range, the interventionwas no longer cost-effective at costs higherTable 3
Incremental cost-effectiveness of SMS intervention: secondary analy
Simulation description
∗
Discounted costs
(2016 USD)
Population adherence under standard care of 40%
Standard care $7049
SMS mean effect with retention benefits $7715
Range† ($7602 to $7813)
Population adherence under standard care of 50%
Standard care $7147
SMS mean effect with retention benefits $7802
Range† ($7703 to $7877)
ICER= incremental cost-effectiveness ratio, QALY=quality-adjusted life year, SMS= short messaging s
∗
Intervention cost=$15USD per patient per year.
† Range is based on variation of the SMS intervention effectiveness alone.
5than $15 per patient per year in most scenarios. At an
intervention cost of $5 per patient per year, the SMS interventions
were cost-effective or very cost-effective in all scenarios tested.
Figure S4, http://links.lww.com/MD/B570 depicts how SMS
intervention cost-effectiveness varies with overall HIV treatment
and care costs. Higher treatment and care costs consistently
increased the ICER of the SMS interventions, driven by increased
spending on medications for individuals with higher adherence
and also increased testing and care costs for individuals who were
living longer. However, SMS interventions remained cost-
effective despite variation in the treatment and care costs.
We also tested the value of the SMS-based adherence
interventions by simultaneously varying the adherence effective-
ness input, the retention effectiveness input and ASC during
sensitivity analyses (Appendix A, http://links.lww.com/MD/
B570). In all analyses, retention benefits improved the ICER
compared to adherence benefits alone. We also calculated the
ICER using unadjusted life years and using HSUV from Kenya.
Although the average discounted life years changed, the
incremental difference remained similar and the SMS interven-
tions remained cost-effective (Appendix B, http://links.lww.com/
MD/B570). We tested an attenuated efficacy of the SMS
intervention over 1, 5, and 10 years. Assuming lifetime
intervention costs (Appendix C, http://links.lww.com/MD/
B570), they remained cost-effective in most scenarios, but
survival benefits were attenuated (ICER $897–$5924/QALY).
With a 1-time intervention cost, the SMS intervention remained
very cost-effective with an improved ICER ($465–$977/QALY)
(Appendix D, http://links.lww.com/MD/B570). The intervention
was very cost-effective or cost-effective across most scenarios.ses with adherence and retention effects.
Discounted
QALY
ICER
(USD/QALY)
Undiscounted mean
survival time, years
12.52 Reference 22.11
13.32 $834 24.01
(13.10 to 13.51) ($955 to $776) (23.56 to 24.40)
12.73 Reference 22.53
13.49 $864 24.35
(13.30 to 13.64) ($803 to $978) (23.97 to 24.66)
ervice.
Figure 2. A multivariate sensitivity analysis varying intervention costs, intervention effectiveness, ASC, and average CD4 count at ART initiation. Individuals were
assumed to start ART with no waiting period, consistent with the test and treat guidelines. Thresholds at which the intervention was no longer cost-effective can be
seen when a variable is increased 1 level and the box turns blue. ART=antiretroviral therapy, ASC=adherence under standard care.
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We evaluated how the cost-effectiveness of the SMS interventions
would change under test and treat guidelines in this scenario. We
made an assumption that through earlier identification of HIV
cases, average CD4 counts at ART initiation would rise from the
current average of 126cells/mm3 to an average of 500cells/mm3.6Table 4 lists the outcomes of SMS interventions under the base
case assumption of threshold based care (ie, initiate ART when
CD4 count is <500cells/mm3) compared to a test and treat
assumption (ie, immediate ART initiation at simulation start,
irrespective of CD4 count). The base case ICER of $1037/QALY
increased to $2283/QALY under test and treat guidelines
(Table 4). If average CD4 counts were as high as 500cells/
3 [16]
Table 4
Incremental cost-effectiveness of SMS intervention under assumptions of threshold-based treatment guidelines and test and treat
guidelines while varying the ASC and intervention effectiveness.
Simulation description
∗
Treatment guideline
assumption†
Mean discounted
costs (2016 USD)
Discounted
QALY
ICER,
$/QALY
Population adherence under standard care of 40%
Standard care Threshold based $7049 12.52 Reference
SMS mean effect Threshold based $7292 12.79 $920
SMS weak effect Threshold based $7201 12.58 $3043
SMS strong effect Threshold based $7393 12.98 $751
Standard care Test and treat $8075 15.08 Reference
SMS mean effect Test and treat $8226 15.17 $1770
SMS weak effect Test and treat $8204 15.10 $7241
SMS strong effect Test and treat $8234 15.22 $1214
Population adherence under standard care of 50%
Standard care Threshold based $7147 12.73 Reference
SMS mean effect Threshold based $7368 12.94 $1037
SMS weak effect Threshold based $7296 12.78 $3491
SMS strong effect Threshold based $7457 13.10 $812
Standard care Test and treat $8089 15.14 Reference
SMS mean effect Test and treat $8231 15.21 $2283
SMS weak effect Test and treat $8223 15.16 $8903
SMS strong effect Test and treat $8244 15.25 $1460
Population adherence under standard care of 60%
Standard care Threshold based $7255 12.93 Reference
SMS mean effect Threshold based $7460 13.11 $1150
SMS weak effect Threshold based $7387 12.96 $4556
SMS strong effect Threshold based $7518 13.23 $880
Standard care Test and treat $8099 15.20 Reference
SMS mean effect Test and treat $8244 15.25 $2777
SMS weak effect Test and treat $8231 15.21 $11,999
SMS strong effect Test and treat $8256 15.29 $1652
ART=antiretroviral therapy, ASC= adherence under standard care, ICER= incremental cost-effectiveness ratio, QALY=quality-adjusted life year, SMS= short messaging service.
∗
Based on SMS intervention adherence efficacy alone; intervention cost=$15USD per patient per year.
† Test and treat and assumes there is no ART initiation threshold and average population CD4 counts are 500 cell/mm3 at ART initiation. Threshold-based guidelines assume an ART initiation threshold of 500cell/
mm3 and average population CD4 count of 126 cell/mm3 at ART initiation.
Patel et al. Medicine (2017) 96:7 www.md-journal.commm and SMS interventions were only weakly effective, the ICER
ranged from $7241 to $11,999/QALY, which was no longer cost
effective based on WHO threshold.5. Discussion
Our findings suggest that weekly SMS-based interventions to
support HIV treatment are very cost-effective byWHO standards
in Kenya. We explored a wide range of scenarios and
assumptions to strengthen our findings. The base case ICER
for SMS interventions was $1037/QALY, which is below the
WHO very cost-effective threshold of $US 2154/QALY. With
additional retention benefits, the ICER improved to $864/QALY,
making them even more efficient at extending QALYs. In
addition to being an efficient use of funds, they could provide
much-needed support for individuals to remain engaged with the
health system. Furthermore, due to the widespread availability of
cellphones, SMS interventions could be scaled up using
infrastructure that has been developed as a part of an ongoing
cellphone boom. These findings have important implication for
ART delivery programs, which need low-cost ways to address
poor adherence.
In addition to theWHO thresholds for cost-effectiveness, a 2nd
way to evaluate cost-effectiveness is a comparison to past budget-
constrained decisions. A previously studied budget-constrained
decision was to increase the ART initiation threshold from a CD4
count of 200 to 350cells/mm3. Two studies describe the cost-7effectiveness of this change. Braithwaite et al estimated the
ICER of this decision was $2600/QALY. A 2nd independent
study by Walensky et al[14] estimated an ICER of $1200/life year
saved for the same decision. We found the ICER for the SMS
interventions to be $1037/QALY with no retention benefits and
$864/QALY with retention benefits. Our results suggest that
investment in SMS-based adherence interventions for individuals
receiving ART could have comparable or better value than the
previously implemented decision of expanded ART.
Data beyond the 1-year trial period are lacking, so we tested an
attenuated intervention effect and compared the results to the base
case lifetime effectiveness assumption. In themost extreme scenario
of attenuated intervention effect, we assumed the intervention
effects were lost 1 year after the intervention, and individuals who
were newly adherent returned to a previous level of nonadherence.
The attenuated intervention effects reduced long-term health
benefits because of an increased risk of viral rebound and
resistance. The average QALY of the SMS intervention simulated
cohort was reduced, thus reducing the incremental QALY
difference between SMS interventions and standard care. Howev-
er, the SMS-based adherence interventions remained cost-effective,
because 1 year of improved adherence resulted in health
improvements that meaningfully altered the average prognosis
of the simulated cohort. It was clear that lifelong application of
SMS interventionswas less cost-effective than a 1-year application;
however, the potential for added patient satisfaction and
engagement might justify some of the cost.
[31]
Patel et al. Medicine (2017) 96:7 MedicineThe WHO test and treat guidelines are an important
intervention to improve HIV outcomes, and assuming higher
average CD4 count at ART initiation, we find it would improve
health outcomes over threshold based guidelines. In these
analyses, we assumed that the test and treat strategy would
increase average CD4 count at ART initiation from the current
126 to 500cells/mm3.With standard care, the discountedQALYs
rose from the base case value of 12.73 to 15.14 QALYs, because
of the increased average CD4 count (Table 4). We explored the
value of the SMS interventions in a scenario of a fully
implemented test and treat strategy. The ICER of the SMS
interventions increased from $1037/QALY in the base case to
$2283/QALY. Although the ICER of SMS interventions was
increased, they remained cost-effective suggesting they would
maintain their value under test and treat guidelines. However, the
ICER crossed the cost-effective threshold under assumptions of a
weak intervention effectiveness at every level of ASC tested,
suggesting there is a risk of the SMS interventions not being cost-
effective (ICER=$7241–$11,999/QALY).
We found that average CD4 count at the time of initiating ART
influenced SMS intervention cost-effectiveness, with lower
average CD4 counts at initiation being associated with a lower
ICER (Fig. 2). Detection of HIV remains delayed in many parts of
Kenya, and some argue that the benefits of earlier treatment
initiation would not be realized without 1st addressing issues
earlier in the cascade of HIV care.[28,29] If ART were initiated
immediately upon detection in some Kenya cohorts today, the
value of SMS interventions would be consistent with the results
presented in the base case because average CD4 counts at HIV
detection remain low. However, if average CD4 counts were to
rise because of improvements earlier in the cascade of care,
targeting of the SMS intervention to individuals with low CD4
counts could be necessary. Regardless, SMS interventions could
efficiently facilitate the success of expanded treatment recom-
mendations, since adherence will be increasingly critical within a
larger population of treated individuals.
This study has several important limitations. First, the
adherence data came from only 2 RCTs in Kenya. We only
used the individual level adherence data from Pop-Eleches et al
trial in our model. However, these studies were conducted in
different settings within Kenya and included broad populations,
and data may be generalizable to broader Kenyan settings.[11,23]
Additionally, we accounted for these limitations by varying the
ASC widely to understand the impact on the final ICER. As more
refined individual level adherence data becomes available, this
limitation can be further addressed in subsequent iterations of the
model. A 2nd limitation is that our analysis did not include
secondary transmission outcomes. Treatment as prevention, or
the now accepted concept that suppressed viral load prevents
further transmission, was not formally considered and would
have led to greater health system savings. The cost-effectiveness
of these interventions would be improved if those benefits were
modeled and they might be cost-savings in the long run.
Nonetheless, we were able to confirm SMS interventions are cost-
effective based on individual level outcomes.
Aside from cost-effectiveness, the rationale for using public
funds to support SMS interventions would be stronger if the
interventions have positive health and economic externalities or if
the interventions help improve outcomes for poor beneficiaries
and therefore increase equity in health outcomes.[30] SMS
interventions may meet both of these additional criteria. One
positive externality of improved adherence is the prevention of
further transmission. Low-cost ways to improve adherence are8critical to prevent the spread of HIV in Kenya and beyond.
Additionally, SMS interventions are advantageous for reaching
rural and extremely poor individuals. Cell phones are commonly
available and the programmatic costs are relatively low due to
automation of most tasks. The engagement SMS program may
have an additional reach, in that individuals were not required to
own their own phones and could access the service through a
friend, family member, or treatment partner. Further research is
needed to identify the most efficient ways to implement SMS
programs and to investigate the relationship between retention
and adherence.
Use of SMS to improve ART outcomes is cost-effective in
Kenya and could be valuable in similar settings. In addition to
being a cost-effective way to improve health outcomes, these
programs have the opportunity to increase communication
between individuals and providers in a tangible way. Introduc-
tion of these programs in extended settings would allow for
further investigation of differential benefits in subgroups. Cost-
effective measures are urgently needed to achieve the UNAIDS
90-90-90 targets, which aims for 90% of worldwide HIV cases to
be virally suppressed by 2020.
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